Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD ASTRA
2024-517901-97-00Phase 2Authorised
- Sponsor
- Východoslovenský onkologický ústav
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Východoslovenský onkologický ústav. Primary endpoint: 5-year biochemical control rate. Planned start Jun 2023; status: authorised.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-517901-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517901-97-00.